Fit-For-Purpose Biomarker Development
Source: Worldwide Clinical Trials
By Michael F Murphy, MD, PhD; Jasna Klicic Badoux, PhD; Tom Zhang, PhD

During a drug discovery and development process, a drug candidate is first characterized in a preclinical setting to assess its performance characteristics. This confirms the engagement of a molecule with a pathophysiologically relevant molecular target and informs the efficacy and safety of the product once a candidate molecule is introduced into clinical development. Here, we highlight the essential framework of a “fit-for-purpose” biomarker development strategy, emphasizing strategic and transactional engagements with clinical research organizations.
access the White Paper!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Cell & Gene? Subscribe today.
Subscribe to Cell & Gene
X
Subscribe to Cell & Gene
Worldwide Clinical Trials
This website uses cookies to ensure you get the best experience on our website. Learn more